"An individual went conservative on this board...months ago and suggested that with only the four or five indications... We have targeted...the valuation was well north of $70 Billion."

To get to that $70 Billion my defensive nature tells me that we want to make sure that the first indications go to separate or opposing competing interests because the residual indications of LL will best be realized and enhanced only after the first indications are actually in the marketplace and demonstrating their worth scientifically and medically. My thinking is that licensing to early competing interests will help ensure less temptation for an opportunistic licensee to slow-walk or selfishly mothball a LL indication.